A Phase 1 Safety Study of Dengusiil in Healthy Adults

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT04035278

Recruitment Status : Completed

First Posted : July 29, 2019

Last Update Posted : January 3, 2024

View this study on the modernized ClinicalTrials.gov

Sponsor:

Collaborator:

PPD Australia Pty Ltd

Information provided by (Responsible Party):

Serum Institute of India Pvt. Ltd.

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Recruitment Status :	Completed
Actual Primary Completion Date :	June 11, 2021
Actual Study Completion Date :	June 11, 2021

Publications of Results:

Gunale B, Farinola N, Yeolekar L, Shrivastava S, Girgis H, Poonawalla CS, Dhere RM, Arankalle V, Chandra Mishra A, Mehla R, Kulkarni PS. A Phase 1, double-blind, randomized, placebo-controlled study to evaluate the safety and immunogenicity of a tetravalent live attenuated dengue vaccine in adults. Vaccine. 2023 Aug 31;41(38):5614-5621. doi: 10.1016/j.vaccine.2023.07.045. Epub 2023 Jul 31.

To Top